| Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification NJ Izzo, CM Yuede, KM LaBarbera, CS Limegrover, C Rehak, R Yurko, ... Alzheimer's & Dementia 17 (8), 1365-1382, 2021 | 54 | 2021 |
| Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein CS Limegrover, R Yurko, NJ Izzo, KM LaBarbera, C Rehak, G Look, ... Journal of Neuroscience Research 99 (4), 1161-1176, 2021 | 28 | 2021 |
| Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer’s disease GM Rishton, GC Look, ZJ Ni, J Zhang, Y Wang, Y Huang, X Wu, NJ Izzo, ... ACS Medicinal Chemistry Letters 12 (9), 1389-1395, 2021 | 25 | 2021 |
| Alzheimer’s protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity CS Limegrover, H LeVine III, NJ Izzo, R Yurko, K Mozzoni, C Rehak, ... Journal of Neurochemistry 157 (4), 1316-1330, 2021 | 24 | 2021 |
